As a physician-scientist in the Division of Hematologic Malignancies at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Dr. Dalton has a clinical specialty in myeloid leukemias and a research laboratory that focuses on the study of DNA mutations that drive those leukemias. In particular, he is working to better understand DNA mutations in the spliceosome, which occur in many patients with MDS and AML and are currently difficult to treat. He uses bone marrow and blood samples generously donated by patients, together with cell ‘models’ that he genetically engineers in the lab, to understand what these DNA mutations do and how they might be targeted with new treatments. His work has led to identification of vulnerabilities in cells containing these mutations that he aims to translate into novel therapeutic approaches in MDS and AML.